Filing Flows › GoodRx Holdings (GDRX) › Q2 2026 › vs Q2 2025
GoodRx Holdings (GDRX) Q2 2026 vs Q2 2025 (year over year)
GoodRx Holdings's revenue fell $2.7M (-1%) from $203M in Q2 2025 to $200M in Q2 2026. The biggest changes: Prescription transactions revenue −$36.7M (-26%); Pharma Direct revenue +$26.6M (+76%); Subscription revenue +$8.1M (+39%). Operating margin 11.8% against 13.2% (-1.4 pts).
GoodRx Holdings, Q2 2026: revenue $200M (-1% year over year), operating margin 11.8%, net earnings $8.5M, operating cash flow $80.8M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 11.8% | 13.2% | -1.4 pts |
| Net margin | 4.3% | 6.3% | -2.1 pts |
| Free cash flow margin | 40.2% | 24.2% | +15.9 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Prescription transactions revenue | $106M | $143M | −$36.7M | -26% |
| Pharma Direct revenue | $61.6M | $35.0M | $26.6M | +76% |
| Subscription revenue | $28.5M | $20.5M | $8.1M | +39% |
| Other revenue | $3.9M | $4.6M | −$683K | -15% |
| Revenue | $200M | $203M | −$2.7M | -1% |
| Operating profit | $23.6M | $26.8M | −$3.2M | -12% |
| Costs & expenses | $177M | $176M | $518K | +0.3% |
| Pre-tax earnings | $15.5M | $19.6M | −$4.1M | -21% |
| Other expense, net | $8.2M | $7.2M | $934K | +13% |
| Cost of revenue | $21.0M | $13.3M | $7.6M | +57% |
| Research & development | $26.7M | $29.9M | −$3.2M | -11% |
| Sales & marketing | $82.0M | $84.9M | −$2.9M | -3% |
| General & admin | $24.8M | $28.4M | −$3.6M | -13% |
| Other operating costs | $22.3M | $19.7M | $2.5M | +13% |
| Net earnings | $8.5M | $12.8M | −$4.3M | -34% |
| Income tax | $6.9M | $6.7M | $196K | +3% |
| Depreciation & amortization | $22.3M | $19.7M | $2.5M | +13% |
| Share-based compensation | $16.6M | $21.4M | −$4.8M | -23% |
| Working capital & other | $33.4M | −$4.4M | $37.8M | — |
| Operating cash flow | $80.8M | $49.6M | $31.3M | +63% |
| Free cash flow (OCF − capex) | $80.5M | $49.2M | $31.3M | +64% |
| Capital expenditures | $362K | $390K | −$28K | -7% |
Questions
How much did GoodRx Holdings's revenue grow year over year in Q2 2026?
GoodRx Holdings's revenue fell $2.7M (-1%) from $203M in Q2 2025 to $200M in Q2 2026.
What drove GoodRx Holdings's revenue change in Q2 2026?
Prescription transactions revenue −$36.7M (-26%); Pharma Direct revenue +$26.6M (+76%); Subscription revenue +$8.1M (+39%).